The FDA has agreed to permit limited use of Novartis’ Zelnorm (tegaserod maleate) by some patients through a restricted access program, following the drug’s voluntary withdrawal over cardiovascular ...

WASHINGTON (Reuters) - Novartis will further restrict access to its irritable bowel syndrome drug Zelnorm, reserving it for the sickest patients, the company and U.S. health regulators said on ...

US WorldMeds announced that the Food and Drug Administration (FDA) has approved the reintroduction of Zelnorm (tegaserod) for the treatment of irritable bowel syndrome with constipation (IBS-C) in ...

Novartis, the manufacturer of Zelnorm, has notified the FDA that they will no longer provide Zelnorm (tegaserod maleate) under a treatment investigational new drug application (T-IND) protocol to ...

WASHINGTON — A widely prescribed drug for severe constipation is being taken off the market after it was linked to a higher risk of heart attacks and strokes, federal regulators said Friday. Doctors ...

The popular constipation prescription Zelnorm will no longer be available. Swiss drug maker Novartis has agreed to stop selling Zelnorm after it was linked to serious side effects including heart ...

WASHINGTON, April 2 (UPI) -- Novartis suspended U.S. sales of Zelnorm after the irritable bowel syndrome drug was found to be associated with an increased risk of heart problems and stroke, but ...

An investment in promotional strategy has helped fuel new prescription growth for Novartis brands Diovan and Zelnorm, chief marketing officer Kurt Graves said yesterday during UBS’ Global Life ...

How can you convince sufferers to seek treatment with a new drug if they don't understand the problem it can solve? This was one of the key consumer challenges faced by Novartis in establishing ...

Novartis had high hopes that its drug Zelnorm would become a blockbuster treatment for irritable bowel syndrome. Instead, it has become a more-than-effective antidote for its market-darling status.